- Home
- DIBS vs MGNX Comparison
DIBS vs MGNX Comparison
Compare DIBS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIBS
- MGNX
- Stock Information
- Founded
- DIBS 2000
- MGNX 2000
- Country
- DIBS United States
- MGNX United States
- Employees
- DIBS N/A
- MGNX N/A
- Industry
- DIBS Catalog/Specialty Distribution
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- DIBS Consumer Discretionary
- MGNX Health Care
- Exchange
- DIBS Nasdaq
- MGNX Nasdaq
- Market Cap
- DIBS 99.7M
- MGNX 99.7M
- IPO Year
- DIBS 2021
- MGNX 2013
- Fundamental
- Price
- DIBS $3.63
- MGNX $1.47
- Analyst Decision
- DIBS Hold
- MGNX Hold
- Analyst Count
- DIBS 1
- MGNX 6
- Target Price
- DIBS N/A
- MGNX $3.20
- AVG Volume (30 Days)
- DIBS 87.2K
- MGNX 833.7K
- Earning Date
- DIBS 11-07-2025
- MGNX 11-04-2025
- Dividend Yield
- DIBS N/A
- MGNX N/A
- EPS Growth
- DIBS N/A
- MGNX N/A
- EPS
- DIBS N/A
- MGNX N/A
- Revenue
- DIBS $88,640,000.00
- MGNX $165,495,000.00
- Revenue This Year
- DIBS $2.87
- MGNX N/A
- Revenue Next Year
- DIBS $3.26
- MGNX N/A
- P/E Ratio
- DIBS N/A
- MGNX N/A
- Revenue Growth
- DIBS 3.21
- MGNX 303.47
- 52 Week Low
- DIBS $2.30
- MGNX $0.99
- 52 Week High
- DIBS $4.39
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- DIBS 68.20
- MGNX 36.72
- Support Level
- DIBS $3.51
- MGNX $1.82
- Resistance Level
- DIBS $4.10
- MGNX $1.69
- Average True Range (ATR)
- DIBS 0.23
- MGNX 0.15
- MACD
- DIBS 0.05
- MGNX -0.04
- Stochastic Oscillator
- DIBS 65.31
- MGNX 5.33
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.